Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717229 | 0.80 | GAA (0.47) | NOTUMNPC1RAB9AKMT2AMIF | |
| SCHEMBL8522855 | 0.70 | CDK2 (0.42) | NOTUMNPC1LMNARAB9AKMT2A | |
| SCHEMBL2413135 | 0.67 | GAA (0.66) | NOTUMNPC1LMNARAB9AKMT2A | |
| SCHEMBL2752440 | 0.65 | NOTUM (0.44) | NOTUMLMNAKMT2AFLT3CA1 | |
| SCHEMBL28947957 | 0.64 | LMNA (0.42) | NOTUMNPC1LMNARAB9AKMT2A | |
| SCHEMBL1896258 | 0.64 | NOTUM (0.47) | NOTUMNPC1LMNARAB9AKMT2A | |
| SCHEMBL6075526 | 0.64 | KMT2A (0.53) | NOTUMNPC1LMNARAB9AKMT2A | |
| SCHEMBL4042811 | 0.64 | NOTUM (0.42) | NOTUMNPC1LMNARAB9AKMT2A | |
| SCHEMBL15657033 | 0.60 | NOTUM (0.47) | NOTUMNPC1LMNAKMT2AFLT3 | |
| SCHEMBL23557718 | 0.60 | PTGS2 (0.63) | FLT3CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-20050032820-A1 | Novel spiro compounds | MSD K.K. (JP) | 2005-02-10 | — | — | US | disclosed |
| WO-2003076443-A9 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2005-01-20 | — | — | WO | disclosed |
| EP-1483266-A1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076443-A1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032820-A1 | Novel spiro compounds | NR3C2, GPR119, NPY2R | NOTUM 3126/4885NPC1 1175/4885LMNA 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.